Prof. Adrian Ochsenbein (Bern University Hospital, Switzerland) presented the results of the open-label, non-randomised combined phase 1 and 2 study looking at newly diagnosed acute myeloid leukaemia (AML) treatment with hypomethylating agent azacitidine. These results showed that better clinical benefit could be achieved by the addition of the anti-CD70 monoclonal antibody cusatuzumab. Cusatuzumab in combination with azacitidine appeared safe and tolerable .
Leukaemia stem cells are known to express the surface markers CD70 and CD27, and there is substantial pre-clinical data to suggest that cusatuzumab blocks CD70–CD27 signalling. The authors hypothesised that combining cusatuzumab with azacitidine would eradicate leukaemia stem cells. This study provided the first-in-human data of this combination.
The study enrolled 12 patients with newly diagnosed AML, who received 1 infusion with cusatuzumab, ranging from 1-20 mg/kg, followed after 14 days ...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Anti-BCMA/anti-CD38 in refractory multiple myeloma Next Article
Long-term data of ropeginterferon alpha-2b in polycythaemia vera »
Table of Contents: ASH 2019
Sickle Cell Disease
Plenary Scientific Session
CAR T and Beyond
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.